Cargando…

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial

Autologous stem cell transplant (ASCT) remains the standard of care for consolidation after induction therapy for eligible patients with newly diagnosed myeloma. In recent clinical trials comparing ASCT to delayed ASCT, patients aged over 65 were excluded. In real-world practice stem cell transplant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pawlyn, Charlotte, Cairns, David A., Menzies, Tom, Jones, John R., Jenner, Matthew W., Cook, Gordon, Boyd, Kevin D., Drayson, Mark T., Kaiser, Martin F., Owen, Roger G., Gregory, Walter, Morgan, Gareth J., Jackson, Graham H., Davies, Faith E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719065/ https://www.ncbi.nlm.nih.gov/pubmed/33297668 http://dx.doi.org/10.3324/haematol.2020.262360

Ejemplares similares

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
por: Croft, James, et al.
Publicado: (2020)

Molecular profiling in myeloma
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
por: Coulson, Amy Beth, et al.
Publicado: (2022)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
por: Cook, Gordon, et al.
Publicado: (2019)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
por: Shah, V, et al.
Publicado: (2018)

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
por: Jones, John R., et al.
Publicado: (2019)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2010)

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue
por: Wu, Ping, et al.
Publicado: (2015)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
por: Striha, Alina, et al.
Publicado: (2018)

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2011)

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
por: Royle, Kara-Louise, et al.
Publicado: (2022)

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
por: Boyle, Eileen M, et al.
Publicado: (2015)

The evolving role and utility of off-label drug use in multiple myeloma
por: Stoeckle, James H, et al.
Publicado: (2021)

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?
por: Pawlyn, C, et al.
Publicado: (2016)

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma
por: Ahmedzai, Sam H., et al.
Publicado: (2019)

Patient experience of whole body diffusion weighted magnetic resonance imaging (WB-MRI) for staging myeloma
por: Otero, S, et al.
Publicado: (2015)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma
por: Mitchell, Jonathan S., et al.
Publicado: (2015)

Hyperhaploid karyotypes in multiple myeloma
por: Sawyer, Jeffrey R., et al.
Publicado: (2017)

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients
por: Panopoulou, Aikaterini, et al.
Publicado: (2023)

Heat shock proteins in multiple myeloma
por: Zhang, Lei, et al.
Publicado: (2014)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5itnjdeh4fha44e1to1o22lgll